Bristol-Myers Squibb Company (BMY) has been under the microscope on Wall Street due to its volatile market performance. The company recently faced drops in share value, despite being highlighted as a leader in the market with a jump to a 93 RS Rating. BMY has attracted investor attention due to its promising dividend returns and is said to be one of the best performing dividend stocks to buy now. Amping up its commitment to biotechnology, the company has successfully acquired cell therapy partner,
2seventy bio, for $286 million. Regarding drug development,
BMY has received approval from the European Commission for Breyanzi in Non-Hodgkin Lymphoma treatment, and the U.S. FDA has greenlit its first-in-class Muscarinic Agonist,
COBENFY, for schizophrenia treatment in adults. The company’s Q4 results have topped estimates, despite a challenging market environment and a projected steeper drop in 2025 revenue. This resilience has caught the eye of Jim Cramer, who praises BMY’s potential multi-billion-dollar catalyst.
Bristol-Myers Squibb BMY News Analytics from Mon, 06 May 2024 07:00:00 GMT to Sat, 15 Mar 2025 07:19:54 GMT -
Innovation 5
- Information 7
- Rumor 0
